Connect your AI

Vaxcyte, Inc. PCVX Debt Securities, Available-for-Sale, Unrealized Loss Position

Debt Securities, Available-for-Sale, Unrealized Loss Position at other companies

ModernaMRNA

——

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s debt securities, available-for-sale, unrealized loss position.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s debt securities, available-for-sale, unrealized loss position?: Vaxcyte, Inc. (PCVX) reported debt securities, available-for-sale, unrealized loss position of $1.6B in Q1 2026.
How has Vaxcyte, Inc.'s debt securities, available-for-sale, unrealized loss position changed year-over-year?: Vaxcyte, Inc.'s debt securities, available-for-sale, unrealized loss position increased by 33.3% year-over-year, from $1.2B to $1.6B.